v3.26.1
Segment Reporting
 12 Months Ended
Dec. 31, 2025
Segment Reporting  
Segment Reporting

16. Segment Reporting

The Company has one reportable segment relating to the discovery and development of novel orally bioavailable, small molecule therapies across a broad range of diseases driven by STAT3 with high unmet need.

The Company’s CODM, its Chief Executive Officer and Chief Financial Officer, manages the Company’s operations at a company-wide level for the purposes of allocating resources. The key measure of segment profit or loss that the CODM uses to allocate resources and assess financial performance is the Company’s net loss, which is utilized to evaluate the progress of its research and development programs and other expense categories. The CODM makes decisions using this information on a company-wide basis.

The table below shows a reconciliation of the Company’s net loss, including the significant expense categories regularly provided to and reviewed by the CODM, as computed under GAAP, to the Company’s net loss in the consolidated statements of operations and comprehensive loss (in thousands):

​

​

​

​

​

​

​

​

​

For the Year Ended

​

​

December 31, 

​

  ​ ​ ​

2025

  ​ ​ ​

2024

Direct research and development expenses by program:

 

​

  ​

 

​

  ​

TTI-101:

 

​

  ​

 

​

  ​

HCC

​

$

3,183

​

$

8,583

IPF

​

 

4,683

​

 

6,703

mBC

​

 

(262)

​

 

2,182

Preclinical, CMC, and other (unallocated) (1)

​

 

688

​

 

969

TTI-109

​

 

5,371

​

 

1,193

Unallocated research and development expense:

​

 

  ​

​

 

  ​

Personnel costs

​

 

3,329

​

 

2,988

Consultant fees and other costs (2)

​

 

1,019

​

 

1,032

General and administrative expense:

​

 

  ​

​

 

  ​

Personnel costs

​

 

3,505

​

 

2,085

Other general and administrative expenses (3)

​

 

5,232

​

 

2,372

Interest income

​

 

(1,375)

​

 

(747)

Other (income) expense, net

​

 

(7,159)

​

 

2,037

Net loss

​

$

(18,214)

​

$

(29,397)

(1)Preclinical, chemistry, manufacturing and control (CMC), and other (unallocated) costs include preclinical testing, CMC, and other direct research and development expenses that are not allocated to a specific program.
(2)Consultant fees and other costs includes expenses incurred for research and development consultants as well as payroll costs for employees within the research and development function.
(3)Other general and administrative expenses include professional fees, accounting services, rent, and other overhead and administrative expenses.

Assets provided to the CODM are consistent with those reported on the consolidated balance sheets. The Company does not have intra-entity sales or transfers.